April 9 Update: Password now required; please click "Join The Seminar Here" below to see the password information. If you cannot get in, please email roakley@partners.org

Please click the link below to join the webinar:

https://dfci.zoom.us/j/274761262?pwd=dkJ5TVpVd1dlSDRhVjF2aHNJT0xsZz09

Or iPhone one-tap : US: +13126266799,,274761262#  or +19292056099,,274761262#
Or Telephone: US: +1 312 626 6799  or +1 929 205 6099  or +1 346 248 7799  or +1 669 900 6833  or +1 253 215 8782  or +1 301 715 8592
Webinar ID: 274 761 262 
Password: 2635808

Hide

The DF/HCC Connect:Science seminar series offers remote participation through Zoom (create an account here) to pull our community of faculty, trainees, and lab staff together during this difficult time and it promotes engagement during these next several weeks. We plan to involve speakers who are leaders in cancer biology, immune oncology and other fields from across the world. Thank you to the Leukemia & Lymphoma Society for partnering with DF/HCC in this effort, which will be broadcast to researchers around the globe and recorded for subsequent viewing.

The series will begin on March 23 and be held every Monday, Tuesday, Thursday and Friday. All talks will be begin at 12 PM EST.

For more information about this seminar series, email: dfhcc@partners.org

Organized by:

Upcoming Seminars

APRIL 10

Deciphering and targeting clonal evolution in myeloid malignancies

  • Ross Levine, MD
    ROSS LEVINE, MD

    Memorial Sloan Kettering Cancer Center

APRIL 13

Overcoming obstacles to response to checkpoint blockade immunotherapy

  • Jedd Wolchok, MD, PhD
    JEDD WOLCHOK, MD, PHD

    Memorial Sloan Kettering Cancer Center

APRIL 14

Molecular Dissection of Tumor Evolution

  • Tyler Jacks, PhD
    TYLER JACKS, PHD

    Koch Institute for Integrative Cancer Research

APRIL 16

How Aneuploidy causes Tumorigenesis 

  • Angelika Amon, PhD
    ANGELIKA AMON, PHD

    Massachusetts Institute of Technology

APRIL 17

The Origin of Complex Cancer Genomes 

  • David Pellman, MD
    DAVID PELLMAN, MD

    Dana-Farber Cancer Institute

APRIL 20

Computational Modeling of Tumor Immunity

  • Xiaole Shirley Liu, PhD
    XIAOLE SHIRLEY LIU, PHD

    Dana-Farber Cancer Institute

APRIL 21

Relapse-fate arises early in the evolution of human AML and B-ALL

  • John Dick, PhD, FRS
    JOHN DICK, PHD, FRS

    University Health Network

APRIL 23

Cancer Prevention and Early Detection in the Precision Medicine Era

  • Timothy Rebbeck, PhD
    TIMOTHY REBBECK, PHD

    Dana-Farber Cancer Institute

APRIL 24

Regulating the immune response to cancer

  • Nick Haining, BCh, BM
    NICK HAINING, BCH, BM

    Merck Oncology

APRIL 27

TITLE TBD

  • Dana Pe’er, PHD
    DANA PE’ER, PHD

    Memorial Sloan Kettering Cancer Center

APRIL 30

Metabolic gatekeepers in B-cell malignancies

  • Markus Müschen, MD, PhD
    MARKUS MÜSCHEN, MD, PHD

    City of Hope Comprehensive Cancer Center

MAY 1

Gasdermin E suppresses tumor growth by activating anti-tumor immunity

  • Judy Lieberman, MD, PhD
    JUDY LIEBERMAN, MD, PHD

    Boston Children's Hospital

MAY 7

Atlases as roadmaps to understanding tumors

  • Aviv Regev, PhD
    AVIV REGEV, PHD

    Broad Institute

MAY 8

WHAT WE CAN LEARN ABOUT THE MICROENVIRONMENT FROM TUMORS THAT DO OR DON’T METASTASIZE

  • Zena Werb, PhD
    ZENA WERB, PHD

    University of California, San Francisco

Past Seminars

 

APRIL 9

Towards personalized microRNA therapeutics in cancer

  • Frank Slack, PhD
    FRANK SLACK, PHD

    Beth Israel Deaconess Medical Center

APRIL 7

T cell genome engineering at the clinic

  • Carl June, MD
    CARL JUNE, MD

    University of Pennsylvania Perelman School of Medicine

APRIL 6

Phenotypic screening approaches to oncology therapeutic discovery

  • Todd Golub, MD
    TODD GOLUB, MD

    Broad Institute and Dana-Farber Cancer Institute

APRIL 3

Targeted protein degradation for cancer therapeutics

  • Benjamin Ebert, MD, PhD
    BENJAMIN EBERT, MD, PHD

    Dana-Farber Cancer Institute

APRIL 2

Addressing cancer clonal heterogeneity: Developing personalized cancer vaccines

  • Catherine Wu, MD
    CATHERINE WU, MD

    Dana-Farber Cancer Institute

MARCH 31

Cancer Genomes in 3-Dimensions

  • Bradley Bernstein, MD, PhD
    BRADLEY BERNSTEIN, MD, PHD

    Massachusetts General Hospital

MARCH 30

Understanding Metastasis

  • Joan Massague, PhD
    JOAN MASSAGUE, PHD

    Memorial Sloan Kettering Cancer Center

MARCH 27

Stem Cell Clonality and the Niche

  • Leonard Zon, MD
    LEONARD ZON, MD

    Boston Children's Hospital

MARCH 26

Remembrance of Things Past: Turning on Fetal Hemoglobin to Treat Hemoglobin Disorders

  • Stuart H. Orkin, MD
    STUART H. ORKIN, MD

    Dana-Farber Cancer Institute

MARCH 24

Does The Microbiome Promote Human Cancer?

  • Matthew L. Meyerson, MD, PhD
    MATTHEW L. MEYERSON, MD, PHD

    Dana-Farber Cancer Institute

MARCH 23

The von Hippel-Lindau Hereditary Cancer Syndrome: From Bedside to Bench to Bedside

  • William G. Kaelin, Jr., MD
    WILLIAM G. KAELIN, JR., MD

    Dana-Farber Cancer Institute